Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt.
J Crohns Colitis. 2008 Dec;2(4):296-303. doi: 10.1016/j.crohns.2008.04.002. Epub 2008 Jun 26.
Traditional medical treatments for ulcerative colitis (UC) are still compromised by its adverse effects and not potent enough to keep in remission for long-term periods. So, new therapies that are targeted at specific disease mechanisms have the potential to provide more effective and safe treatments for ulcerative colitis. Probiotics is recently introduced as a therapy for ulcerative colitis. In the present study, Lactobacillus acidophilus was selected as a probiotic therapy to investigate its effects in oxazolone-induced colitis model in rats that mimics the picture in human. The rats were grouped (8 rats each) as normal control group (Group I), Group II served as untreated oxazolone-induced colitis, Group III oxazolone-induced colitis treated with probiotic L. acidophilus (1×10(7) colony-forming units (CFU)/mL/day oral for 14 days), Group IV oxazolone-induced colitis treated with olsalazine (60 mg/kg/day oral for 14 days), Group V oxazolone-induced colitis treated with probiotic L. acidophilus and olsalazine in the same doses and duration. Disease activity index (DAI) was recorded, serum levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and intrleukin-6 (IL-6) was assessed as inflammatory markers and the histopathological picture of the colon of each rat was studied. Disease activity index (DAI) showed significant positive correlation with the elevated serum levels of CRP (r=0.741, p<0.05), TNF-α (r=0.802, p<0.05) and IL-6 (r=0.801, p<0.05). Treatment with either L. acidophilus (group III) or olsalazine (group IV) resulted in significant reduction in serum levels of CRP, TNF-α and IL-6, as well as disease activity index (DAI). Treatment with combination of L. acidophilus and olsalazine (group V) offered more significant reduction in serum levels of CRP, TNF-α, IL-6 and disease activity index (DAI) when compared to either group II (untreated group), group III (treated with L. acidophilus) or group IV (treated with olsalazine). So, it was concluded that L. acidophilus probiotic could be recommended as adjuvant therapy in combination with olsalazine to achieve more effective treatment for ulcerative colitis. For application in human, this needs to be verified in further clinical studies.
传统的溃疡性结肠炎（UC）治疗方法仍受到其不良反应的影响，并且不能长期保持缓解。因此，针对特定疾病机制的新疗法有可能为溃疡性结肠炎提供更有效和安全的治疗方法。益生菌最近被引入溃疡性结肠炎的治疗方法。在本研究中，选择嗜酸乳杆菌作为益生菌治疗方法，以研究其在模仿人类疾病的氧化偶氮甲烷诱导结肠炎模型中的作用。将大鼠分为正常对照组（I 组）（8 只/组）、未经治疗的氧化偶氮甲烷诱导结肠炎组（II 组）、用益生菌嗜酸乳杆菌（1×10（7）个菌落形成单位（CFU）/mL/天口服 14 天）治疗的氧化偶氮甲烷诱导结肠炎组（III 组）、用柳氮磺胺吡啶（60mg/kg/天口服 14 天）治疗的氧化偶氮甲烷诱导结肠炎组（IV 组）、用相同剂量和时间的益生菌嗜酸乳杆菌和柳氮磺胺吡啶治疗的氧化偶氮甲烷诱导结肠炎组（V 组）。记录疾病活动指数（DAI），评估血清 C-反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）水平作为炎症标志物，并研究每只大鼠结肠的组织病理学图片。疾病活动指数（DAI）与血清 CRP 水平升高呈显著正相关（r=0.741，p<0.05）、TNF-α（r=0.802，p<0.05）和 IL-6（r=0.801，p<0.05）。用嗜酸乳杆菌（III 组）或柳氮磺胺吡啶（IV 组）治疗可显著降低血清 CRP、TNF-α和 IL-6 水平以及疾病活动指数（DAI）。与未经治疗的组 II（未治疗组）、用嗜酸乳杆菌治疗的组 III（用嗜酸乳杆菌治疗组）或用柳氮磺胺吡啶治疗的组 IV（用柳氮磺胺吡啶治疗组）相比，用嗜酸乳杆菌和柳氮磺胺吡啶联合治疗（V 组）可更显著降低血清 CRP、TNF-α、IL-6 和疾病活动指数（DAI）水平。因此，可以得出结论，嗜酸乳杆菌益生菌可以作为辅助治疗与柳氮磺胺吡啶联合应用，以实现更有效的溃疡性结肠炎治疗。为了在人类中应用，这需要在进一步的临床研究中得到验证。
